Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Combination of subtherapeutic anti-TNF dose with dasatinib restores clinical and molecular arthritogenic profiles better than standard anti-TNF treatment

Abstract Background New medications for Rheumatoid Arthritis (RA) have emerged in the last decades, including Disease Modifying Antirheumatic Drugs (DMARDs) and biologics. However, there is no known cure, since a significant proportion of patients remain or become non-responders to current therapies...

Full description

Bibliographic Details
Main Authors: Lydia Ntari, Christoforos Nikolaou, Ksanthi Kranidioti, Dimitra Papadopoulou, Eleni Christodoulou-Vafeiadou, Panagiotis Chouvardas, Florian Meier, Christina Geka, Maria C. Denis, Niki Karagianni, George Kollias
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Journal of Translational Medicine
Subjects:
Arthritis
Tyrosine Kinase inhibitors
Dasatinib
Bosutinib
Tofacitinib
Anti-hTNF
Online Access:https://doi.org/10.1186/s12967-021-02764-y

Internet

https://doi.org/10.1186/s12967-021-02764-y

Similar Items